Log in or register to see all Alerts
New HTA Decisions in England
June 2020
Drug name
DARZALEX® (daratumumab)
Company
Janssen
Decision date
30/06/2020
Therapeutic area
Blood and immune system conditions
Therapeutic sub area
Blood and bone marrow cancers
Decision
Not recommended
Indication
Untreated multiple myeloma.
Decision Detail
This was a terminated appraisal.
Summary
NICE was unable to make a recommendation on daratumumab (Darzalex) with lenalidomide and dexamethasone for untreated multiple myeloma, because the company did not provide an evidence submission. NICE will review this decision if the company decides to make a submission.